EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access · CC BY-NC 4.0

Efficacy and safety of iGlarLixi versus IDegAsp by baseline β‐cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli‐D study

Weijun Gu iD, Xiaohong Wu iD, Minlu Zhang, Xinyi Wang, Qin Du, Lei Kang, Felipe Lauand, Agustina Alvarez, Yiming Mu iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70181 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Weijun Gu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, First Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Insulin Aspart, Insulin Glargine. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To compare the efficacy and safety of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) with insulin degludec plus insulin aspart (IDegAsp) by β‐cell function in exploratory analyses of the Soli‐D study. Materials and Methods Soli‐D was a 24‐week, multicentre, randomised, open‐label study in Chinese adults with uncontrolled type 2 diabetes (T2D) on oral antidiabetic drugs (OADs). We evaluated glycaemic efficacy, body weight, total insulin daily dose and hypoglycaemia outcomes with iGlarLixi versus IDegAsp by baseline fasting C‐peptide and Homeostasis Model Assessment of β‐cell function (HOMA‐β) quartile measurements.

Results

Among 386 participants, change in glycated haemoglobin (HbA1c), fasting plasma glucose or postprandial glucose at Week 24 showed no interaction with fasting C‐peptide or HOMA‐β quartile. The difference in HbA1c change favoured iGlarLixi versus IDegAsp in fasting C‐peptide quartile 1 (Q1; p = 0.045) and Q2 ( p = 0.023) and HOMA‐β Q1 ( p = 0.025). The proportion of participants with HbA1c

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsInsulin AspartInsulin GlargineInsulin, Long-ActingInsulin-Secreting CellsPeptidesAdultAgedFemaleHumansMaleMiddle AgedBlood GlucoseC-PeptideChinaDrug CombinationsDrug Therapy, CombinationGlycated HemoglobinHypoglycemiaTreatment OutcomeGlucagon-Like Peptide-2 ReceptorEast Asian People

Stichwörter der Autor:innen

GLP‐1 analoguebasal insulinbeta cell functionglycaemic controliGlarLixitype 2 diabetes

Substanzen

Blood GlucoseC-PeptideDrug CombinationsGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsInsulin Aspartinsulin degludec, insulin aspart drug combinationInsulin GlargineInsulin, Long-Acting

Autor:innen und Institutionen

  • Department of Endocrinology, First Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China.
  • Department of Endocrinology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, China.
  • Sanofi, Shanghai, China.
  • Sanofi, Beijing, China.
  • Sanofi, Paris, France.
  • Sanofi, Madrid, Spain.

ORCID-Profile: Weijun Gu, Xiaohong Wu, Yiming Mu

Förderung

  • Sanofi

Zitieren

APA

Gu, W., Wu, X., Zhang, M., Wang, X., Du, Q., Kang, L., Lauand, F., Alvarez, A., & Mu, Y. (2026). Efficacy and safety of iGlarLixi versus IDegAsp by baseline β‐cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli‐D study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70181

Vancouver

Gu W, Wu X, Zhang M, Wang X, Du Q, Kang L, et al. Efficacy and safety of iGlarLixi versus IDegAsp by baseline β‐cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli‐D study. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70181

BibTeX
@article{Gu2026,
  author = {Gu, Weijun and Wu, Xiaohong and Zhang, Minlu and Wang, Xinyi and Du, Qin and Kang, Lei and Lauand, Felipe and Alvarez, Agustina and Mu, Yiming},
  title = {Efficacy and safety of iGlarLixi versus IDegAsp by baseline β‐cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli‐D study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70181}
}
Kostenlos starten →